Find Clinical Trials | Cedars-Sinai

381 results found

Breast

Pfizer, C4391024, Ph3, Open-label, randomized, Br CA, PF-07220060+Letrozole vs CDK4/6+ Letrozole

Primary Objective: To compare the efficacy of PF07220060 in combination with letrozole (Arm A) versus CDK4/6i (investigator s choice: abemaciclib, palbociclib, or ribociclib) in combination with letrozole (Arm B) with respect to progression-free survival (PFS). Secondary Objectives: To ...

Other Female Genital

Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Endometrial Cancer

The purpose of this study is to learn whether an experimental drug called sacituzumab govitecan (also called SG or Trodelvy) can help patients with endometrial cancer that has spread or recurred to live longer compared ...

Melanoma

Pfizer Inc, C4901001, Phase 1A/B, Open Label, Melanoma ,Solid Tumor, PF-07799544

-Primary Objective: This is a first-in-human, open-label, Phase 1a/b master protocol to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of PF-07799544 (also known as ARRY-134) as a single agent and in ...

Other Hematopoietic

Merck,MK2140-010,Ph 3,Randomized, Lymphoma, Zilovertamab vedotin + R-CHP vs R-Chop

Primary Objective: To compare zilovertamab vedotin plus R-CHP with R-CHOP with respect to progression-free survival (PFS) per Lugano response criteria as assessed by blinded independent central review (BICR). Hypothesis (H1): Zilovertamab vedotin plus R-CHP is superior to ...

Melanoma

Regeneron, R3767-ONC-2466, Ph2, open label, Melanoma, Fianlimab Plus Cemiplimab

Primary -Assess Overall Survival (OS) of patients with melanoma treated with Fianlimab Plus Cemiplimab in Expansion Cohorts from R3767-ONC-1613 Secondary -Assess Progression-Free Survival (PFS) -Assess Objective Response Rate (ORR) -Assess Duration of Response (DOR) -Assess Disease Control Rate (DCR) ...